With its unique cTA® and data-driven decision support platform, Flagship offers its pharmaceutical partners robust, actionable data for informed decision making during clinical development SANTA CLARA, Calif., Sept. 18, 2018 /PRNewswire/...

Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue...

Flagship Biosciences has introduced a new menu of services to help drug developers more confidently define their path to success. ActionAssays is a comprehensive catalog of brightfield immunohistochemistry (IHC) assays that provide actionable...